Can I read Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma on EtoBox?

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma by Grande, Enrique (author);Bamias, Aristotelis (author);Galsky, Matthew D. (author);Kikuchi, Eiji (author);Davis, Ian D. (author);Arranz, José Ángel (author);Rezazadeh Kalebasty, Arash (author);Garcia del Muro, Xavier (author);Park, Se Hoon (author);De Giorgi, Ugo (author);Alekseev, Boris (author);Mencinger, Marina (author);Izumi, Kouji (author);Puente, Javier (author);Li, Jian-Ri (author);Bernhard, Sandrine (author);Nicholas, Alan (author);Telliez, Julie (author);De Santis, Maria (author) is a nonfiction available to read on EtoBox.

What is Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma about?

Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients without progressive disease (PD) after induction CTx. IMvigor130 was a randomised, phase 3 study evaluating atezolizumab plus platinum-based CTx (arm A), atezolizumab monotherapy (arm B), or placebo plus platinum-based CTx (arm C) as first-line treatment for mUC. The primary progression-free survival (PFS) analysis showed a statistically significant PFS benefit favouring arm A versus arm C, which did not translate into overall survival (OS) benefit at the final OS analysis. We report exploratory analyses based on response to combination induction treatment (arm A vs arm C) using final OS data. Post-induction OS was analysed for patients without PD during induction (4–6 CTx cycles) who received at least one dose of single-agent atezolizumab/placebo maintenance treatment. Post-progression OS was analysed for patients with PD during induction CTx. Addition of atezolizumab to CTx did not impact OS outcomes, regardless of response to induction CTx, with hazard ratios of 0.84 (95% confidence interval [CI] 0.63–1

Who reads Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma?

Author

Grande, Enrique (author);Bamias, Aristotelis (author);Galsky, Matthew D. (author);Kikuchi, Eiji (author);Davis, Ian D. (author);Arranz, José Ángel (author);Rezazadeh Kalebasty, Arash (author);Garcia del Muro, Xavier (author);Park, Se Hoon (author);De Giorgi, Ugo (author);Alekseev, Boris (author);Mencinger, Marina (author);Izumi, Kouji (author);Puente, Javier (author);Li, Jian-Ri (author);Bernhard, Sandrine (author);Nicholas, Alan (author);Telliez, Julie (author);De Santis, Maria (author)

Publisher

Elsevier BV

Published

2023

Language

EN

Category

nonfiction